A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study
European Journal of Cancer2017Vol. 76, pp. 110–117
Citations Over TimeTop 10% of 2017 papers
Alain Ravaud, Christelle de la Fouchardière, Philippe Caron, A. Doussau, Christine Do Cao, Julien Asselineau, Patrice Rodien, Damien Pouessel, Patricia Nicolli-Sire, Marc Klein, Claire Bournaud-Salinas, Jean-Louis Wémeau, Anne Gimbert, Marie-Quitterie Picat, Delphine Pedenon, Laurence Digue, Amaury Daste, Bogdan Catargi, Jean‐Pierre Delord
Related Papers
- → Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma(2010)86 cited
- → Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).(2021)76 cited
- → Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer(2007)26 cited
- → Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial(2023)14 cited
- → 265O Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial(2020)10 cited